Pay in 4 interest-free payments of $5.91 Learn more
Ships within 48 hours · Estimated delivery Sep 28 - Oct 3
In PIONEER 8, mean weight loss was -1.4% with semaglutide 3 mg, -2.6% with semaglutide 7 mg, -3.7% with semaglutide 14 mg and -0.5% with placebo from baseline to week 26
References Food and Nutrition Board, Institute of Medicine
Tirzepatide (Mounjaro, Zepbound) is a once-weekly subcutaneous injection approved by the FDA for type 2 diabetes management and chronic weight management
Clinical Evidence in Humans The topical evidence base is unusually robust for a research peptide: Facial aging study (71 women, 12 weeks): A GHK-Cu facial cream documented increased skin density and thickness, reduced laxity, improved clarity, and reduced fine lines and depth of wrinkles (PMID 26236730)
US$ 25.02
US$ 27.80
US$ 22.78
US$ 23.11
US$ 20.11
US$ 28.52
US$ 20.54
US$ 26.68
US$ 27.09
US$ 24.66
